Nektar Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NKTR and other ETFs, options, and stocks.

About NKTR

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. 

CEO
Howard W. Robin
CEOHoward W. Robin
Employees
63
Employees63
Headquarters
San Francisco, California
HeadquartersSan Francisco, California
Founded
1990
Founded1990
Employees
63
Employees63

NKTR Key Statistics

Market cap
2.55B
Market cap2.55B
Price-Earnings ratio
-8.68
Price-Earnings ratio-8.68
Dividend yield
Dividend yield
Average volume
706.62K
Average volume706.62K
High today
$74.23
High today$74.23
Low today
$71.79
Low today$71.79
Open price
$73.56
Open price$73.56
Volume
581.03K
Volume581.03K
52 Week high
$109.00
52 Week high$109.00
52 Week low
$21.60
52 Week low$21.60

Stock Snapshot

The current Nektar Therapeutics(NKTR) stock price is $71.79, with a market capitalization of 2.55B. The stock trades at a price-to-earnings (P/E) ratio of -8.68.

On 2026-08-05, Nektar Therapeutics(NKTR) stock traded between a low of $71.79 and a high of $74.23. Shares are currently priced at $71.79, which is 0.0% above the low and -3.3% below the high.

The Nektar Therapeutics(NKTR)'s current trading volume is 581.03K, compared to an average daily volume of 706.62K.

In the last year, Nektar Therapeutics(NKTR) shares hit a 52-week high of $109.00 and a 52-week low of $21.60.

In the last year, Nektar Therapeutics(NKTR) shares hit a 52-week high of $109.00 and a 52-week low of $21.60.

NKTR News

TipRanks 1d
Nektar’s Phase 3 Eczema Trial Moves Forward: What Investors Should Watch

Nektar Therapeutics (NKTR) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more con...

Simply Wall St 2d
Is Global Phase 3 ZENITH AD Rezpegaldesleukin Program Altering The Investment Case For Nektar Therapeutics? - simplywall.st

...

Is Global Phase 3 ZENITH AD Rezpegaldesleukin Program Altering The Investment Case For Nektar Therapeutics? - simplywall.st

Analyst ratings

91%

of 11 ratings
Buy
90.9%
Hold
9.1%
Sell
0%

People also own

Based on the portfolios of people who own NKTR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.